Bukwang Pharmaceutical Statistics

Total Valuation

Bukwang Pharmaceutical has a market cap or net worth of KRW 311.47 billion. The enterprise value is 277.66 billion.

Market Cap	311.47B
Enterprise Value	277.66B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Bukwang Pharmaceutical has 68.45 million shares outstanding. The number of shares has increased by 0.44% in one year.

Current Share Class	n/a
Shares Outstanding	68.45M
Shares Change (YoY)	+0.44%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	19.14%
Owned by Institutions (%)	3.00%
Float	47.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.24
PB Ratio	1.39
P/TBV Ratio	1.42
P/FCF Ratio	8.01
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-18.17
EV / Sales	2.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	7.14

Financial Position

The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.35.

Current Ratio	6.84
Quick Ratio	4.97
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	2.04
Interest Coverage	-4.21

Financial Efficiency

Return on equity (ROE) is -7.09% and return on invested capital (ROIC) is -3.41%.

Return on Equity (ROE)	-7.09%
Return on Assets (ROA)	-2.70%
Return on Capital (ROIC)	-3.41%
Revenue Per Employee	250.77M
Profits Per Employee	-27.59M
Employee Count	554
Asset Turnover	0.37
Inventory Turnover	1.48

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.18% in the last 52 weeks. The beta is -0.17, so Bukwang Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	-0.17
52-Week Price Change	-21.18%
50-Day Moving Average	4,734.20
200-Day Moving Average	5,486.65
Relative Strength Index (RSI)	45.90
Average Volume (20 Days)	500,025

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bukwang Pharmaceutical had revenue of KRW 138.93 billion and -15.29 billion in losses. Loss per share was -223.59.

Revenue	138.93B
Gross Profit	59.28B
Operating Income	-16.05B
Pretax Income	-17.49B
Net Income	-15.29B
EBITDA	-12.04B
EBIT	-16.05B
Loss Per Share	-223.59

Full Income Statement

Balance Sheet

The company has 117.60 billion in cash and 79.30 billion in debt, giving a net cash position of 38.30 billion or 559.53 per share.

Cash & Cash Equivalents	117.60B
Total Debt	79.30B
Net Cash	38.30B
Net Cash Per Share	559.53
Equity (Book Value)	228.97B
Book Value Per Share	3,279.15
Working Capital	166.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 40.45 billion and capital expenditures -1.55 billion, giving a free cash flow of 38.89 billion.

Operating Cash Flow	40.45B
Capital Expenditures	-1.55B
Free Cash Flow	38.89B
FCF Per Share	568.13

Full Cash Flow Statement

Margins

Gross margin is 42.67%, with operating and profit margins of -11.55% and -11.00%.

Gross Margin	42.67%
Operating Margin	-11.55%
Pretax Margin	-12.59%
Profit Margin	-11.00%
EBITDA Margin	-8.66%
EBIT Margin	-11.55%
FCF Margin	27.99%

Dividends & Yields

Bukwang Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.44%
Shareholder Yield	-0.44%
Earnings Yield	-4.91%
FCF Yield	12.49%

Dividend Details

Stock Splits

The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.1.

Last Split Date	Dec 29, 2020
Split Type	Forward
Split Ratio	1.1

Scores

Bukwang Pharmaceutical has an Altman Z-Score of 3.56.

Altman Z-Score	3.56
Piotroski F-Score	n/a